Filter By Industry
Filter By Tag


Biosceptre Press releases

1 - 10 of 13 Press Releases

Sep 07, 2020
Biosceptre is pleased to announce that an agreement has been signed with pre-clinical CAR T development company, Carina Biotech, that will see the advancement of a promising cancer immunotherapy.

Dec 19, 2018
Biosceptre Acting Chair Sir Greg Winter wins Nobel prize, refines focus to Science Advisory Board and cedes to new Chair Andrew Walton-Green

Aug 20, 2018
Biosceptre has initiated its Phase I clinical trial of the peptide vaccine BIL06v, with the first patient treated at the initial trial site on 16th of August 2018.

Mar 01, 2018
The proposed Phase I clinical trial for BIL06v (anti-cancer vaccine) was granted conditional approval by the Bellberry Ethics committee on 21st February 2018.

Dec 14, 2017
Biosceptre has received over £8M into its series A raise which will be used to resource the next stage of the companies' development; progression into the clinic of Biosceptre's first systemic products against novel oncology target nfP2X7.

Jun 13, 2017
The group fosters collaboration throughout the EU on science of Ion Channels and Immune Response

Apr 27, 2017
Biosceptre's appointment of a CMO marks a major milestone in progression to the clinic of its therapeutic anticancer vaccine BIL06v against the novel oncology target nfP2X7.

Mar 16, 2017
Biosceptre's proposed Phase I clinical trial for BIL03s (anti-cancer monoclonal antibody therapy) was granted conditional approval by the Bellberry Ethics committee.

Mar 02, 2017
Biosceptre has published a clinical study demonstrating that its topical drug BIL010t provides a novel, safe and tolerable topical therapy for BCC in the British Journal of Dermatology (BJD)

Dec 14, 2016
Biosceptre is pleased to announce the appointment of its independent Director Sir Gregory Winter as the Chair of the Board of Directors.

Page: 1 2 Next
Biosceptre RSS Feed